A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, PHASE I TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF LIVE RECOMBINANT CANARYPOX ALVAC-HIV VCP205 COMBINED WITH GM-CSF IN HEALTHY, HIV-1 UNINFECTED VOLUNTEERS: